Zimmer Biomet (NYSE:ZBH – Get Free Report) and IceCure Medical (NASDAQ:ICCM – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.
Institutional & Insider Ownership
88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 0.6% of IceCure Medical shares are owned by institutional investors. 1.3% of Zimmer Biomet shares are owned by company insiders. Comparatively, 2.4% of IceCure Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk & Volatility
Zimmer Biomet has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zimmer Biomet | 2 | 14 | 6 | 0 | 2.18 |
| IceCure Medical | 2 | 0 | 3 | 0 | 2.20 |
Zimmer Biomet presently has a consensus price target of $103.00, suggesting a potential upside of 17.07%. IceCure Medical has a consensus price target of $52.50, suggesting a potential upside of 3,006.51%. Given IceCure Medical’s stronger consensus rating and higher possible upside, analysts clearly believe IceCure Medical is more favorable than Zimmer Biomet.
Earnings & Valuation
This table compares Zimmer Biomet and IceCure Medical”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zimmer Biomet | $8.23 billion | 2.04 | $705.20 million | $4.11 | 21.41 |
| IceCure Medical | $3.38 million | 1.72 | -$15.06 million | ($8.52) | -0.20 |
Zimmer Biomet has higher revenue and earnings than IceCure Medical. IceCure Medical is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Zimmer Biomet and IceCure Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zimmer Biomet | 9.48% | 13.12% | 7.23% |
| IceCure Medical | -427.67% | -174.26% | -112.58% |
Summary
Zimmer Biomet beats IceCure Medical on 11 of the 14 factors compared between the two stocks.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
About IceCure Medical
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.
